Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Situated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

Researchers identified the enzyme CMPK2 as a possible target for therapies aiming to prevent metabolic dysfunction-associated ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

If it makes it through to market, UA022 would follow in the footsteps of pioneering KRAS inhibitors Amgen’s Lumakras (sotorasib) and Mirati’s Krazati (adagrasib), which have been approved as ...

Currently, Amgen’s Lumakras (sotorasib) and Bristol-Myers Squibb/Mirati’s Krazati (adagrasib) are the only two approved KRAS G12C inhibitors, although several others are in clinical development.

today announced preliminary clinical data for the triplet combination of avutometinib and sotorasib plus defactinib in the RAMP 203 Phase 1/2 study in KRAS G12C mutant advanced non-small cell lung ...

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

US FDA Puts Clinical Hold on Atara's Trials for Cancer Cell Therapies Atara Biotherapeutics said on Tuesday the U.S. health regulator had placed a clinical hold on its trials for cancer cell ...

After hours: 7:50:10 p.m. EST ...

After hours: 24 January at 19:52:19 GMT-5 ...